Cell Point (India) Board of Directors
Get the latest insights into the leadership at Cell Point (India). Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Mohan Prasad Panday | Managing Director |
| Mr. Bala Balaji Panday | Whole Time Director |
| Mrs. Kiranmai Panday | Executive Director |
| Mr. Ananda Ravada | Independent Director |
| Ms. Kakshayani Sekharamantri | Independent Director |
Cell Point (India) Share price
CELLPOINT
18.3
0.25 (1.39%)NSE
BSE
Last updated on 4 Sep, 2025 | 15:31 IST
BUYSELL
Today's High
18.65
Today's Low
17.65
52 Week Low
15.60
52 Week High
35.35
The current prices are delayed, login to your account for live prices
LoginCell Point (India) FAQs
The board at Cell Point (India) consists of experienced professionals, including Mr. Mohan Prasad Panday , Mr. Bala Balaji Panday , and others, overseeing the company’s strategic and corporate governance.
Directors at Cell Point (India) are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Mohan Prasad Panday is the current chairman at Cell Point (India).
Executive directors at Cell Point (India) are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Cell Point (India) adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Cell Point (India), board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.